Daraxonrasib Demonstrates Initial Antitumor Activity in RAS-Mutant Lung Cancer
More than 30% of patients with RAS-mutated non-small-cell lung cancer saw tumors shrink in a small trial, researchers said.
9 Articles
9 Articles
The drug Rasonque (daraxonrasib), which received historic FDA approval by doubling the survival time in pancreatic cancer, has also been shown to be effective against lung cancer, the deadliest type of cancer.
Daraxonrasib shows durable responses in RAS-mutant lung cancer
Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a Phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.
Medical Xpress
NewswiseDaraxonrasib demonstrates initial antitumor activity in RAS-mutant lung cancer
Daraxonrasib, an oral RAS inhibitor therapy, achieved durable responses in pretreated patients with RAS-mutant non-small cell lung cancer (NSCLC) in a phase 1/2 trial led by The University of Texas MD Anderson Cancer Center.
Mariasanchezmonge Oncology Study in 'NEJM' Daraxonrasib, the drug that has initiated a revolution in the treatment of pancreatic cancer, also shows promising results in lung cancer. As pointed out by the authors of the study published in The New England Journal of Medicine, there are well-founded reasons to rely on its efficacy in other types of tumors. In this case, it is known that RAS mutations, which constitute the target of this inhibitor, …
Coverage Details
Bias Distribution
- 60% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
